Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
NEW ORLEANS, Dec. 02, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 12, 2016 to file lead plaintiff applications in a securities class action lawsuit against Mylan N.V. (Nasdaq:MYL), if they purchased the Company’s securities between February 21, 2012 and October 7, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
What You May Do
If you purchased securities of Mylan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 12, 2016.
About the Lawsuit
Mylan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On September 2, 2016, it was reported that the Centers for Medicare & Medicaid Services had “informed Mylan that it incorrectly classified EpiPen as a generic under the Medicaid rebate program, which caused financial consequences for federal and state governments by reducing the amount of quarterly rebates Mylan owed for its product.”
Then, on October 7, 2016, Mylan announced that it had reached a $465 million settlement with the Department of Justice regarding the classification of EpiPen and that it had received a request from the SEC for documents related to the Medicaid rebate program.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
